The Corporate Partnership Programme brings together non-industry and key IAS industry partners to drive important conversations across the HIV continuum of care.
In 2021, it expanded from the flagship Industry Liaison Forum to bring two additional groups under its umbrella – the Towards an HIV Cure: Industry Collaboration Group and the HIV Vaccine Industry Partnership Group. The expansion strengthens collaboration around specific pressing needs in the HIV response.
The Industry Liaison Forum convenes biomedical industry and non-industry stakeholders, including community-based organizations, on a broad range of topics relevant for the strong response of the pharmaceutical, diagnostics and other industry sectors to HIV.
The Towards an HIV Cure: Industry Collaboration Group aims to identify and prioritize ways for biomedical industry and non-industry stakeholders to work together in HIV cure research and development.
The HIV Vaccine Industry Partnership Group brings together the biomedical industry and non-industry stakeholders to address the complexities of HIV vaccine research and development.
Each group offers stakeholders opportunities to inform research agendas; explore (faster) ways to get new technologies to markets; and mobilize the biomedical industry and non-industry (academic, civil society and global health institutions) towards meeting the groups’ goals.